Skip to content

Use of lasers to prevent oral mucositis in children 2 to 15 years old receiving cancer treatment

Effectiveness of photobiomodulation pre-conditioning for prevention of oral mucositis in children aged between 2 to 15 years receiving chemotherapy - a randomized controlled trial - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/105972
Enrollment
58
Registered
2026-03-11
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C96Z- Other specified malignant neoplasms of lymphoid, hematopoietic and related tissue

Interventions

Intervention1: Laser Photobiomodulation: Patients will receive the basic oral care instructions, in addition to intraoral photobiomodulation with a diode laser (650 nm
power 100 mW, energy density 6 J/cm The number of irradiation points are as follows: 8 on the buccal mucosa (4 on each side), 4 on the labial mucosa (2 upper and 2 lower), 8 on the tongue (3 on the

Sponsors

Dr Samrudhi Sanjay Sawant
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Children between the age group of 2-15 years who are admitted to Zulekha Institute of Oncology with leukaemias, lymphomas, or solid tumours are recommended to receive chemotherapy. 2.No existing oral mucosal lesions at baseline. 3.Ability to comply with follow-up.

Exclusion criteria

Exclusion criteria: 1. Prior radiotherapy to the head and neck region. 2. Malignancy of the oral cavity. 3. Juvenile Diabetes. 4. Undergoing any other procedures to prevent oral Mucositis 5. Children unwilling or unable to participate.

Design outcomes

Primary

MeasureTime frame
Occurrence and severity of oral mucositis Measurement Tool: Oral Mucositis Assessment Scale (OMAS) Parameters Assessed: Erythema (0 2) Ulceration/pseudomembrane (0 3) Total OMAS score (0 5) Average score across all intraoral sitesTimepoint: 7 days and 14 days after initiation of first chemotherapy cycle

Secondary

MeasureTime frame
NILTimepoint: NIL

Countries

India

Contacts

Public ContactDr H T Ajay Rao

Yenepoya Dental College, Mangalore

drajayrao@gmail.com9845085048

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026